TNF and amyloidosis: Overall, the BBB-penetrating TNF-α inhibitor had better therapeutic indices than etanercept, a non-BBB-penetrating TNF-α inhibitor [28] expected to modulate only peripheral but not CNS TNF-α, in the mouse model of amyloidosis [37].